Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system

Trends in Pharmacological Sciences

Volumn 28, Issue 1, 2007, Pages 32-38

  Larsen, Brandon T ^a   Campbell, William B ^a   Gutterman, David D ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSATRIENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR SYSTEM; CELL MIGRATION; DIABETES MELLITUS; DNA POLYMORPHISM; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THROMBOCYTE ADHESION; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION, PULMONARY; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR STRUCTURE; VASODILATION;

EID: 33845944050     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.11.002     Document Type: Review

References (77)

1. Spiecker M., and Liao J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 433 (2005) 413-420
2. Larsen B.T., et al. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur. J. Clin. Invest. 36 (2006) 293-300
3. Spiecker M., and Liao J. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc. Med. 16 (2006) 204-208
4. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
5. Wu S., et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271 (1996) 3460-3468
6. Daikh B.E., et al. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271 (1994) 1427-1433
7. Scarborough P.E., et al. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab. Rev. 31 (1999) 205-234
8. Campbell W.B., et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78 (1996) 415-423
9. Ca channels. Circulation 107 (2003) 769-776
10. Campbell W.B., et al. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. Med. Sci. Monit. 7 (2001) 578-584
11. Ca channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H491-H499
12. Fisslthaler B., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
13. Urakami-Harasawa L., et al. Importance of endothelium-derived hyperpolarizing factor in human arteries. J. Clin. Invest. 100 (1997) 2793-2799
14. + channels. Circulation 99 (1999) 3132-3138
15. + channels. Circulation 103 (2001) 1992-1998
16. Kaw S., and Hecker M. Endothelium-derived hyperpolarizing factor, but not nitric oxide or prostacyclin release, is resistant to menadione-induced oxidative stress in the bovine coronary artery. Naunyn Schmiedebergs Arch. Pharmacol. 359 (1999) 133-139
17. Shimokawa H., et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J. Cardiovasc. Pharmacol. 28 (1996) 703-711
18. Bauersachs J., et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
19. Pfister S.L., et al. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am. J. Physiol. 261 (1991) H843-H852
20. Pritchard Jr. K.A., et al. Atherogenic concentrations of low-density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products. Am. J. Pathol. 136 (1990) 1383-1391
21. Spiecker M., et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110 (2004) 2132-2136
22. Yasar U., et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13 (2003) 715-720
23. Fornage M., et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109 (2004) 335-339
24. Ohtoshi K., et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331 (2005) 347-350
25. Lee C.R., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15 (2006) 1640-1649
26. Wei Q., et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis (2006). http://www.sciencedirect.com/science/journals 10.1016/j.atherosclerosis.2006.02.021 (http://www.sciencedirect.com/science/journals)
27. Node K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
28. Pritchard Jr. K.A., et al. 14,15-Epoxyeicosatrienoic acid promotes endothelial cell dependent adhesion of human monocytic tumor U937 cells. Biochem. Biophys. Res. Commun. 167 (1990) 137-142
29. Liu Y., et al. The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16747-16752
30. Sun J., et al. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90 (2002) 1020-1027
31. Davis B.B., et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2222-2227
32. Kip1. J. Biol. Chem. 278 (2003) 29619-29625
33. Michaelis U.R., et al. Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 321-326
34. Michaelis U.R., and Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol. Ther. 111 (2006) 584-595
35. Michaelis U.R., et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17 (2003) 770-772
36. Potente M., et al. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J. Biol. Chem. 277 (2002) 15671-15676
37. Wang Y., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 314 (2005) 522-532
38. Pozzi A., et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem. 280 (2005) 27138-27146
39. Zhang B., et al. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J. Biol. Chem. 281 (2006) 905-914
40. Fleming I., and Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47 (2006) 629-633
41. Michaelis U.R., et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell Sci. 118 (2005) 5489-5498
42. Krotz F., et al. Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 595-600
43. Fitzpatrick F.A., et al. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J. Biol. Chem. 261 (1986) 15334-15338
44. Jiang H., et al. Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J. Biol. Chem. 279 (2004) 36412-36418
45. s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276 (2001) 15983-15989
46. King L.M., et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol. Pharmacol. 61 (2002) 840-852
47. Sandberg M., et al. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J. Biol. Chem. 275 (2000) 28873-28881
48. Przybyla-Zawislak B.D., et al. Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 64 (2003) 482-490
49. Yang W., et al. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension 45 (2005) 681-686
50. Imig J.D., et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
51. Zhao X., et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15 (2004) 1244-1253
52. Davis B.B., et al. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J. Pharmacol. Exp. Ther. 316 (2006) 815-821
53. Fang X., et al. Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J. Pharmacol. Exp. Ther. 314 (2005) 260-270
54. Fang X., et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2412-H2420
55. Zhao X., et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R188-R196
56. Katakam P.V., et al. Cytochrome P450 activity and endothelial dysfunction in insulin resistance. J. Vasc. Res. 37 (2000) 426-434
57. Miller A.W., et al. Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1524-H1531
58. Fang X., et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-α. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H55-H63
59. Zhao X., et al. PPAR-α activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2187-H2195
60. Falck J.R., et al. Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem. Biophys. Res. Commun. 114 (1983) 743-749
61. Turk J., et al. Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets. Biochim. Biophys. Acta 835 (1985) 1-17
62. Zeldin D.C., et al. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138 (1997) 1338-1346
63. Yoshida S., et al. Possible involvement of arachidonic acid metabolites of cytochrome P450 monooxygenase pathway in vasopressin-stimulated glycogenolysis in isolated rat hepatocytes. Arch. Biochem. Biophys. 280 (1990) 346-351
64. Daikh B.E., et al. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271 (1994) 1427-1433
65. Scarborough P.E., et al. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab. Rev. 31 (1999) 205-234
66. Zhu D., et al. Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am. J. Physiol. Lung Cell. Mol. Physiol. 278 (2000) L335-L343
67. Zhu D., et al. Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H1526-H1533
68. Yaghi A., et al. Cytochrome P450 metabolites of arachidonic acid but not cyclooxygenase-2 metabolites contribute to the pulmonary vascular hyporeactivity in rats with acute Pseudomonas pneumonia. J. Pharmacol. Exp. Ther. 297 (2001) 479-488
69. Stephenson A.H., et al. Differential effects of 5,6-EET on segmental pulmonary vasoactivity in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H2153-H2161
70. Stephenson A.H., et al. Inhibition of cytochrome P-450 attenuates hypoxemia of acute lung injury in dogs. Am. J. Physiol. 270 (1996) H1355-H1362
71. Stephenson A.H., et al. 5, 6-Epoxyeicosatrienoic acid reduces increases in pulmonary vascular resistance in the dog. Am. J. Physiol. 275 (1998) H100-H109
72. Pokreisz P., et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47 (2006) 762-770
73. Ivey C.L., et al. Involvement of cytochrome P-450 enzyme activity in the control of microvascular permeability in canine lung. Am. J. Physiol. 275 (1998) L756-L763
74. Dhanasekaran A., et al. Protective effects of epoxyeicosatrienoic acids (EETs) on human endothelial cells from the pulmonary and coronary vasculature. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H517-H531
75. Smith K.R., et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2186-2191
76. Jiang J.G., et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65 (2005) 4707-4715
77. Dzau V.J. Pathobiology of atherosclerosis and plaque complications. Am. Heart J. 128 (1994) 1300-1304